XML 54 R61.htm IDEA: XBRL DOCUMENT v2.3.0.15
Segment Reporting (Details 2) (USD $)
3 Months Ended9 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2011
Sep. 30, 2010
Reconciliation of segment profits to Income Before Taxes    
Income Before Taxes$ 2,352,000,000$ 498,000,000$ 5,753,000,000$ 2,354,000,000
Unallocated:    
Interest income45,000,00023,000,000137,000,00057,000,000
Interest expense(189,000,000)(173,000,000)(557,000,000)(539,000,000)
Equity income from affiliates161,000,000236,000,000354,000,000417,000,000
Depreciation and amortization  (5,566,000,000)(5,515,000,000)
Research and development(1,954,000,000)(2,322,000,000)(6,048,000,000)(6,552,000,000)
Restructuring costs(119,000,000)(50,000,000)(773,000,000)(864,000,000)
Legal reserve (950,000,000)(500,000,000)(950,000,000)
Gain on AstraZeneca asset option exercise   443,000,000
Operating Segments [Member]
    
Reconciliation of segment profits to Income Before Taxes    
Income Before Taxes7,064,000,0006,449,000,00021,094,000,00019,523,000,000
Other profits [Member]
    
Reconciliation of segment profits to Income Before Taxes    
Income Before Taxes31,000,00053,000,00067,000,000168,000,000
All Other Segment [Member]
    
Reconciliation of segment profits to Income Before Taxes    
Income Before Taxes709,000,000598,000,0002,080,000,0001,945,000,000
Adjustments [Member]
    
Reconciliation of segment profits to Income Before Taxes    
Income Before Taxes242,000,00073,000,000718,000,000323,000,000
Unallocated [Member]
    
Unallocated:    
Interest income45,000,00023,000,000137,000,00057,000,000
Interest expense(189,000,000)(173,000,000)(557,000,000)(539,000,000)
Equity income from affiliates47,000,00098,000,00062,000,00098,000,000
Depreciation and amortization(619,000,000)(699,000,000)(1,814,000,000)(1,985,000,000)
Research and development(1,954,000,000)(2,322,000,000)(6,048,000,000)(6,552,000,000)
Amortization of purchase accounting adjustments(1,306,000,000)(1,540,000,000)(4,249,000,000)(5,576,000,000)
Restructuring costs(119,000,000)(50,000,000)(773,000,000)(864,000,000)
Legal reserve (950,000,000)(500,000,000)(950,000,000)
Gain on AstraZeneca asset option exercise   443,000,000
Other expenses, net$ (890,000,000)$ (464,000,000)$ (2,384,000,000)$ (1,792,000,000)